{"title":"Recent Advancements in the Management of Neuropathic Pain","authors":"Anas Hamdan, R. Gálvez","doi":"10.35516/jjps.v16i2.1505","DOIUrl":null,"url":null,"abstract":"Neuropathic pain is defined as ‘pain arising as a direct consequence of a lesion or disease affecting the Somatosensory system, regarding the most important aspects of analgesic treatment in NP its strongly advised to make use of a confirmatory questionnaire for NP Dx, such as DN4 or LANSS, as the Screening Tools. Administer analgesic medications in accordance with the strong evidence presented in NP. Keep in mind the medications that have been given the approval for NP. Tricyclic antidepressants, selective serotonin reuptake inhibitors (SNRIs; duloxetine, venlafaxine), and gabapentinoids; pregabalin and gabapentin; alone or in combination with topical (lidocaine patch, capsaicin patch) are all indicated as first-line analgesics for patients with peripheral NP. If a medication from the first line is unsuccessful, try another medication from the same group or move on to the second line. Tramadol and oxycodone are both considered to be analgesics of the second line. Tapentadol as a replacement drug in cases of persistent pain, it may be necessary to mix medications that work via distinct mechanisms of action. Alternatively, in the event that pharmacology is unsuccessful, analgesic invasive treatments may be combined with drugs.","PeriodicalId":14719,"journal":{"name":"Jordan Journal of Pharmaceutical Sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jordan Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35516/jjps.v16i2.1505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Neuropathic pain is defined as ‘pain arising as a direct consequence of a lesion or disease affecting the Somatosensory system, regarding the most important aspects of analgesic treatment in NP its strongly advised to make use of a confirmatory questionnaire for NP Dx, such as DN4 or LANSS, as the Screening Tools. Administer analgesic medications in accordance with the strong evidence presented in NP. Keep in mind the medications that have been given the approval for NP. Tricyclic antidepressants, selective serotonin reuptake inhibitors (SNRIs; duloxetine, venlafaxine), and gabapentinoids; pregabalin and gabapentin; alone or in combination with topical (lidocaine patch, capsaicin patch) are all indicated as first-line analgesics for patients with peripheral NP. If a medication from the first line is unsuccessful, try another medication from the same group or move on to the second line. Tramadol and oxycodone are both considered to be analgesics of the second line. Tapentadol as a replacement drug in cases of persistent pain, it may be necessary to mix medications that work via distinct mechanisms of action. Alternatively, in the event that pharmacology is unsuccessful, analgesic invasive treatments may be combined with drugs.
期刊介绍:
The Jordan Journal of Pharmaceutical Sciences (JJPS) is a scientific, bi-annual, peer-reviewed publication that will focus on current topics of interest to the pharmaceutical community at large. Although the JJPS is intended to be of interest to pharmaceutical scientists, other healthy workers, and manufacturing processors will also find it most interesting and informative. Papers will cover basic pharmaceutical and applied research, scientific commentaries, as well as views, reviews. Topics on products will include manufacturing process, quality control, pharmaceutical engineering, pharmaceutical technology, and philosophies on all aspects of pharmaceutical sciences. The editorial advisory board would like to place an emphasis on new and innovative methods, technologies, and techniques for the pharmaceutical industry. The reader will find a broad range of important topics in this first issue.